Previous Close | €0.00 |
AI Value | n/a |
Upside potential | n/a% |
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity treatments, and rare blood disorders. Headquartered in Denmark, the company holds a leading position in the diabetes market, with its insulin and GLP-1 receptor agonists (e.g., Ozempic, Wegovy) driving significant revenue. Novo Nordisk operates in over 170 countries and maintains a strong competitive advantage through its extensive R&D pipeline and focus on chronic disease management. The company’s vertically integrated manufacturing and global distribution network further solidify its market dominance.
Leading in GLP-1 and obesity research, with multiple Phase 3 trials ongoing. Holds key patents for semaglutide (Ozempic/Wegovy).
Novo Nordisk remains a high-quality play on diabetes and obesity, with strong pricing power and pipeline optionality. Near-term risks include Wegovy supply bottlenecks and Lilly’s competitive threat, but the long-term growth trajectory is intact. Valuation remains premium but justified by market leadership.
Novo Nordisk 2022 Annual Report, Q3 2023 earnings call, Bloomberg Pharma Analysts.
Historical valuation data is not available at this time.